Argentum Pharmaceuticals LLC

Company overview. Argentum Pharmaceuticals LLC is a privately held, New York-based generic pharmaceutical company co-founded by CEO Jeffrey R. Gardner. It has no public ticker and is not a subsidiary. Public directories put its headcount in the roughly 10–50 employee range with estimated annual revenue in the low single-digit millions (figures from third-party databases such as Kona Equity and SignalHire; the company does not publish financials). The founding year is not clearly established in public sources (one data aggregator lists 2000, but this is unverified).

Products / services / operations. Argentum describes itself as a "new kind of generic pharmaceutical company" that develops, acquires, and markets generic drugs while using the America Invents Act's post-grant review system to challenge what it calls weak or "evergreened" drug patents. It pairs patent clearance early in the generic development cycle with strategic manufacturing and distribution partnerships — its public filings identify KVK-Tech as its manufacturing and marketing partner — and a proprietary AI-based data analytics platform used to screen patent claims. It is an operating company, not a shell licensor; it does not hold or assert a monetization patent portfolio.

Patent-litigation posture. The tracked case data shows one appearance: Argentum as plaintiff (petitioner) at the PTAB against Novartis AG in 2017, with zero appearances as a defendant. That profile fits a patent-challenger business model rather than an NPE — Argentum initiates inter partes reviews to clear generic entry paths and does not sue on its own patents. Notably, the activity sits at the PTAB, not in plaintiff-friendly district courts like the Eastern District of Texas.

Notable cases or context. The tracked matter is Argentum Pharmaceuticals LLC v. Novartis AG (IPR2017-01063), a joined IPR challenging Novartis' U.S. Patent No. 9,187,405 covering the multiple sclerosis drug Gilenya (fingolimod). After the Board upheld the patent, Argentum's appeal was dismissed for lack of Article III standing (Argentum Pharm. LLC v. Novartis Pharm. Corp., 956 F.3d 1374 (Fed. Cir. 2020)); the Supreme Court declined review. Separately, Argentum publicly announced a January 2021 settlement with Bausch Health and Kaken terminating its IPR over the JUBLIA (efinaconazole) patent, consistent with its pattern of resolving challenges through settlement.